Vitamin D in Patients with Kidney Disease: Cautiously Optimistic

Ravi Thadhani*, Myles Wolf

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Nephrologists are well aware of the therapeutic effects of activated vitamin D in managing secondary hyperparathyroidism. Beyond bone and mineral metabolism, however, we are now beginning to appreciate the effects of activating the vitamin D receptor (VDR) in other cell types. Our group and others recently found a survival advantage associated with injectable vitamin D therapy in hemodialysis populations. The observational nature of these studies, however, subjects them to the possibility that confounding and bias may have accounted for their results. Therefore, it is unclear if indeed a survival benefit exists, if harm is incurred with this therapy or if activation of the VDR in cell types other than bone, intestine, and the parathyroid gland are applicable to our patients with kidney disease. The range of studies being planned include those targeting the cardiovascular effects of VDR activation, further understanding of the prevalence and consequences of vitamin D deficiency in patients with kidney disease, trials to examine the effects of VDR activation on intermediate cardiovascular and noncardiovascular endpoints, and trials targeting mortality endpoints. If consistent with the recent observations, these studies may provide nephrologists with an intervention to alter the otherwise poor outcomes in patients with kidney disease.

Original languageEnglish (US)
Pages (from-to)22-26
Number of pages5
JournalAdvances in Chronic Kidney Disease
Issue number1
StatePublished - Jan 2007


  • Cardiovascular disease
  • Hemodialysis survival
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Vitamin D in Patients with Kidney Disease: Cautiously Optimistic'. Together they form a unique fingerprint.

Cite this